B
Bull
Bull · 25%PBM
$4.72
Scenario price
$3.055
+0.119 (+3.91%)At close
Loading chart…
- High
- 3.140
- Open
- 3.020
- VWAP
- 3.05
- Volume
- 24.52K
- Mkt Cap
- —
- Low
- 2.950
- Amount
- 74.75K
- EV/EBITDA, TTM
- 0.00
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. The Company is focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine. The Company is engaged in addressing unmet mental health needs. It is also focused on an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.
AI analysis of Psyence Biomedical Ltd (PBM)
HoldPsyence Biomedical Ltd is not a good buy right now due to its current price of 3.06, which is significantly down 90.21% year-to-date. The RSI is at 28.64, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting a lack of earnings growth potential. The main risk is the company's high volatility, with a 52-week change of -96.83%.
Valuation Metrics
The current forward P/E ratio for Psyence Biomedical Ltd (PBM) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for PBM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
7.509-28NASDAQ.COMPsyence Biomedical Secures Exclusive Ibogaine Development Deal
8.509-23NASDAQ.COMPsyence BioMed Commits $5 Million to Support U.S. Ibogaine Program
8.509-14NASDAQ.COMPsyence Establishes Texas Ibogaine Research Corporation for U.S. Development
8.508-19NASDAQ.COMPsyence Biomedical Welcomes U.S. Support for Ibogaine Development
8.508-18NewsfilterPsyence BioMed Welcomes Trump's Support for Accelerated Ibogaine Development
PBM FAQ — answered by Alphio AI
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. The Company is focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine. The Company is engaged in addressing unmet mental health needs. It is also focused on an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Psyence Biomedical Ltd is not a good buy right now due to its current price of 3.06, which is significantly down 90.21% year-to-date. The RSI is at 28.64, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting a lack of earnings growth potential. The main risk is the company's high volatility, with a 52-week change of -96.83%.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.